| 纯度 | >90%SDS-PAGE. |
| 种属 | Bovine |
| 靶点 | CATHL4 |
| Uniprot No | P33046 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 131-143aa |
| 氨基酸序列 | ILPWKWPWWPWRR |
| 预测分子量 | 17.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CATHL4重组蛋白的3篇假设性文献摘要，供参考：
1. **《重组鲶鱼CATHL4的分子克隆与原核表达及其抗菌活性分析》**
作者：张伟等
摘要：本研究从斑点叉尾鮰中克隆了CATHL4基因，构建pET-28a重组质粒并在大肠杆菌中诱导表达。纯化后的重组蛋白对嗜水气单胞菌和金黄色葡萄球菌具有显著抑菌活性，为水产养殖抗菌剂开发提供依据。
2. **《CATHL4重组蛋白通过TLR4/NF-κB通路调节鱼类巨噬细胞免疫应答》**
作者：李明华, 王丽
摘要：实验证明CATHL4重组蛋白可激活虹鳟巨噬细胞，促进TNF-α和IL-1β分泌，并证实其通过TLR4受体介导NF-κB信号通路，揭示了其在先天免疫中的调控机制。
3. **《基于圆二色谱分析的重组CATHL4蛋白结构稳定性研究》**
作者：Chen J, et al.
摘要：通过圆二色谱和热变性实验发现，CATHL4在pH 5.0-7.4范围内维持α-螺旋结构，60℃以下结构稳定，为其在复杂生理环境中的应用提供了结构稳定性数据支持。
注：以上文献为模拟示例，实际研究需查阅真实数据库(如PubMed、Web of Science)。
CATHL4. a member of the cathelicidin family, is a cationic host defense peptide (HDP) renowned for its broad-spectrum antimicrobial and immunomodulatory properties. Cathelicidins are evolutionarily conserved across vertebrates and play pivotal roles in innate immunity. These peptides are typically synthesized as inactive precursors with a conserved N-terminal cathelin domain and a variable C-terminal antimicrobial domain, which is proteolytically cleaved to release the mature bioactive peptide. CATHL4. identified in several mammalian species, exhibits a unique amphipathic α-helical structure that enables membrane disruption in pathogens, including bacteria, fungi, and enveloped viruses.
Its mechanism involves electrostatic interactions with negatively charged microbial membranes, leading to permeabilization and cell death. Beyond direct microbicidal activity, CATHL4 modulates immune responses by recruiting immune cells, enhancing phagocytosis, and suppressing excessive inflammation through cytokine regulation. This dual functionality makes it a promising candidate for addressing antibiotic-resistant infections and immune dysregulation disorders.
Recombinant CATHL4 is produced via heterologous expression systems (e.g., E. coli or yeast) to overcome natural low abundance and enable scalable synthesis. Advances in protein engineering have optimized its stability and reduced cytotoxicity toward host cells, broadening therapeutic applicability. Preclinical studies highlight its potential in treating chronic wounds, sepsis, and biofilm-associated infections. However, challenges remain in balancing efficacy, toxicity, and cost-effective production. Ongoing research focuses on structural analogs and delivery systems to enhance pharmacokinetics, positioning CATHL4 as a versatile template for next-generation antimicrobial and immunotherapeutic agents.
×
